Printer Friendly

Acorda Therapeutics Added to NASDAQ Biotechnology Index.

HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has been selected for addition to the Nasdaq Biotechnology Index, which will be effective at the market's opening on Monday, November 20, 2006. "We are very pleased to be included in the NASDAQ Biotechnology Index and believe that our selection to this index is recognition of Acorda's consistent progress and achievements," said Ron Cohen, M.D., President and CEO of Acorda. "We are committed to delivering on our mission to develop therapies to restore neurological function to people with spinal cord injury, multiple sclerosis and other disorders of the nervous system."

The NASDAQ Biotechnology Index was launched in 1993 and includes contains securities of NASDAQ-listed companies that meet minimum requirements, including market value, average daily share volume, and seasoning as a public company, among other criteria. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Amex: IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules[TM] (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 15, 2006
Words:457
Previous Article:PrimeEnergy Corporation Announces Third Quarter Earnings and Authorizes Stock Buy Back.
Next Article:Universal Insurance Holdings Subsidiary Receives $25 Million Surplus Note.
Topics:


Related Articles
Can myelin be re-grown?
Tales of Two Medical Startup Companies.
Hudson Valley becomes Silicon Valley of the East.
Alnylam Added to NASDAQ Biotechnology Index.
Panacos Added to NASDAQ Biotechnology Index.
AVI BioPharma Added to NASDAQ Biotech Index.
Acorda Therapeutics to Present at the BioCentury Newsmakers in the Biotech Industry Conference.
OMRIX Biopharmaceuticals To Join NASDAQ Biotechnology Index(R).
Acorda Therapeutics to Present at 7th Annual Fortis Biotech Conference.
Osiris Therapeutics Added to NASDAQ Biotechnology Index.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters